RxDoctor Payments DataLook up a doctor →

Jessica Bordelon, APRN

Nurse Practitioner · Hammond, LANPI 1043585854

Payments from drug & device makers

$77,645in general payments, 2019–2025

Across 702 payments — averaging $110.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Rigel Pharmaceuticals, Inc.$63K
  • Dova Pharmaceuticals$2K
  • EMD Serono, Inc.$1K
  • Novartis$1K
  • Johnson & Johnson$790
  • AstraZeneca$721
  • plus $9K from 54 others

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Rigel Pharmaceuticals, Inc.135$63,009
Dova Pharmaceuticals6$1,538
EMD Serono, Inc.12$1,091
Novartis59$1,050
Johnson & Johnson(2 entities)40$790
AstraZeneca(2 entities)31$721
Eisai Inc.34$646
Pfizer32$594
Takeda Pharmaceuticals U.S.A., Inc.24$550
Bristol Myers Squibb21$428
Gilead(2 entities)11$401
Sanofi15$378
Regeneron Healthcare Solutions, Inc.10$375
Incyte Corporation18$340
Astellas Pharma US Inc12$322
Merck17$320
E.r. Squibb & Sons, L.L.C.13$320
GSK14$294
Ares Trading SA1$293
Daiichi Sankyo Inc.14$259
AVEO Pharmaceuticals, Inc.8$257
Sobi, Inc7$231
Bayer11$205
Amgen10$180
AbbVie7$149
Tersera Therapeutics LLC6$148
Genentech USA, Inc.8$139
Adaptive Biotechnologies Corporation6$137
Seagen Inc.7$126
Array Biopharma Inc6$119
Karyopharm Therapeutics Inc.6$118
Novo Nordisk2$115
Pharmaessentia USA Corporation5$113
Jazz Pharmaceuticals Inc.6$111
Stemline Therapeutics Inc.5$108
Boehringer Ingelheim5$106
Pharmacyclics LLC, An Abbvie Company6$105
Tempus AI, Inc1$96
Taiho Oncology, Inc.5$95
Genmab U.S., Inc.5$90
Sanofi-aventis U.S. LLC1$89
Lilly USA, LLC5$86
Kyowa Kirin, Inc.5$86
Ipsen Biopharmaceuticals, Inc4$75
Pharmacosmos Therapeutics Inc.4$65
Caris MPI, Inc.3$65
Beigene USA, Inc.3$62
Servier Pharmaceuticals LLC3$61
Teva Pharmaceuticals USA, Inc.3$54
Myovant Sciences Inc.2$47
Alnylam Pharmaceuticals Inc.3$45
Acceleron Pharma, Inc.2$43
Blueprint Medicines Corporation2$36
Recordati_rare_diseases_inc.2$34
Veracyte, Inc.2$33
Cumberland Pharmaceuticals, Inc.2$32
Epizyme, Inc.2$32
Puma Biotechnology, Inc.2$32
Fennec Pharmaceuticals, Inc.1$22
Morphosys, US Inc.1$22

How this compares

$77,645 in reported general payments places this provider in the 95th percentile of 969 nurse practitioner providers in Louisiana.

See all nurse practitioner providers in Louisiana →

Medicare billing

Part B allowed, 2024
$50,935
Medicare patients
69
Services billed
1,643

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other nurse practitioner in Hammond

See the full list for Louisiana →

Where these figures come from

Is this you, or does something look wrong? →